STOCK TITAN

GSK plc (GLAXF) Form 4 Filings

GLAXF OTC

Here are the Form 4 insider transactions from GSK plc (GLAXF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow GLAXF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GLAXF filings page.

Rhea-AI Summary

GSK plc, through its wholly owned subsidiary Glaxo Group Limited, reported buying 1,470,000 ordinary shares of Wave Life Sciences Ltd. on 12/11/2025 at a price of $19 per share.

After this transaction, the reporting person beneficially owned 18,245,691 Wave Life Sciences ordinary shares, held indirectly via Glaxo Group Limited. The report reflects GSK plc’s role as a shareholder in Wave Life Sciences rather than a change in GSK plc’s own financial results.